Stem-cell-like CD4 + T cells prey on MHC class II–negative tumors

Despite the absence of MHC class II molecules on tumor cells, stem-cell-like CD4 + T cells specific for tumor neoantigens can mediate profound antitumor effects by licensing antigen-presenting cells and augmenting antitumor CD8 + T cells in the tumor microenvironment and draining lymph nodes.